Immunomonitoring in immunosuppressed patients with pneumonia
Recruiting
- Conditions
- C92.00Z94.81D90Z94.80
- Registration Number
- DRKS00010546
- Lead Sponsor
- niversitätsklinikum Jena
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
age >18 years, written informed consent, iatrogenic or disease-related immunosuppression or opportunistic infection suggesting an underlying immunosuppression
Exclusion Criteria
<18 years, pregnancy, no consent, participation in conflicting study
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection of a predisposing immunodeficiency with an increased risk for pneumonias in immunocompromised patients using flow cytometry
- Secondary Outcome Measures
Name Time Method cytokine analysis (ELISA)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie immune response dysregulation in immunosuppressed pneumonia patients in DRKS00010546?
How does immunomonitoring in DRKS00010546 compare to standard-of-care treatment outcomes for C92.00 pneumonia subtypes?
What biomarkers are associated with prognosis and treatment response in immunosuppressed pneumonia as studied in DRKS00010546?
What adverse events are observed in immunosuppressed pneumonia patients during immunomonitoring in DRKS00010546?
How do combination immunotherapies compare to observational studies like DRKS00010546 in managing immunosuppressed pneumonia?